- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| Do | Thermo Fisher jumps on the US investment bandwagon with $2B in additional spending | ||
| Do | Halozyme sues Merck over subcutaneous Keytruda as licensing talks fall through | ||
| Do | UCB partners with Dr. Pimple Popper in ongoing hidradenitis suppurativa campaign | ||
| Do | BMS shrugs off Cobenfy's schizophrenia hit as it gears up for Alzheimer's psychosis readout, 7 trial starts | ||
| Do | Merck 'willing to work' with Trump administration on price gap between US, international medicines | ||
| Do | Sanofi and Regeneron's high-flying Dupixent on course for an 'inflection year' in COPD | ||
| Do | Roche moves to mitigate US tariff impact amid discussions with global governments | ||
| Do | Lupin recalls nearly 3,000 bottles of OCD medication in the US after subpar stability testing results | ||
| Do | Texas outsourcer in Lilly's compounded tirzepatide lawsuit hit with FDA warning letter | ||
| Mi | Tariff hits to generic drugs could 'blow back on everybody' without supply chain resilience, says USP chief | ||
| Mi | Gilead mounts campaign to close 'HIV gender gap,' calling for greater inclusion of women in UK HIV response | ||
| Mi | Sanofi, Novartis CEOs lambast EU price control as Trump reportedly weighs drug cost parity with other nations | ||
| Mi | With new trial win, Akeso bispecific shows prior success against Keytruda is no 'fluke' | ||
| Mi | Coherus loses commercial chief amid exit from biosimilar space | ||
| Mi | Bristol Myers' schizophrenia drug Cobenfy stumbles as adjunctive treatment, denting blockbuster plan | ||
| Mi | FDA asks Novavax for post-marketing data pledge amid stalled COVID shot review | ||
| Di | 2 years after leaving PhRMA, AstraZeneca opts back in | ||
| Di | Roche to swell US footprint with sweeping $50B investment, furthering pharma's onshoring push | ||
| Di | Galderma, seeking to build $2B product, starts DTC campaign for eczema drug across TV, digital | ||
| Di | Amid industry's onshoring push, Regeneron taps Fujifilm Diosynth for $3B, 10-year commercial manufacturing team-up | ||
| Di | Facing added pressure from Eli Lilly, Novo Nordisk submits for FDA approval of oral GLP-1 obesity drug | ||
| Mo | Gilead's Trodelvy-Keytruda proposal hits goal in first-line triple-negative breast cancer | ||
| Mo | Meribel makes CDMO debut after series of acquisitions in Europe | ||
| Mo | Top leaders at FDA marketing overseer resign, potentially teeing up RFK Jr.'s promised drug ad ban: report | ||
| Mo | Amneal recalls 2 lots of hospital anesthetic over plastic contamination fears |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
